Water Cove Award (2011)
Larry Tiffany is president, CEO and co-founder of DioGenix, an early-stage diagnostics company that engages in the discovery, development, and commercialization of non-invasive monitoring tests to improve the diagnosis of immune-mediated neurodegenerative diseases. Its lead program is designed to provide neurologists with a set of clinical tests to diagnose early-stage MS, segment MS patients into clinical sub-types, and predict response to treatment using non-invasive blood tests. Larry’s team has made considerable progress in the race to cure MS—their blood test for diagnosing MS has the potential to improve the quality of care for patients who currently must endure a long, costly and invasive medical work-up, even in cases where MS cannot be definitively diagnosed. Over time, DioGenix plans to use its strengths and capacity to develop additional tests for indications of significant clinical value.